Alaunos Therapeutics Inc (TCRT)

Apr 24, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World

Apr 24, 2025

Apr 18, 2025

Alaunos Therapeutics announces board member resignation - Investing.com Australia

Apr 18, 2025

Apr 18, 2025

Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada

Apr 18, 2025

Apr 16, 2025

Form 8-KCurrent report - ADVFN

Apr 16, 2025

Apr 15, 2025

Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks

Apr 15, 2025

Apr 14, 2025

Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada

Apr 14, 2025

Apr 14, 2025

Alaunos Therapeutics announces private placement of preferred stock - Investing.com

Apr 14, 2025

Apr 04, 2025

Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st

Apr 04, 2025

Apr 04, 2025

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World

Apr 04, 2025

Apr 03, 2025

11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga

Apr 03, 2025

Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 02, 2025

Mar 31, 2025

Alaunos Therapeutics Inc. (TCRT) reports earnings - qz.com

Mar 31, 2025

Mar 27, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World

Mar 27, 2025

Jan 29, 2025

Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology

Jan 29, 2025

Jan 15, 2025

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World

Jan 15, 2025

Jan 13, 2025

Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology

Jan 13, 2025

Jan 10, 2025

Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology

Jan 10, 2025

Dec 24, 2024

Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World

Dec 24, 2024

Dec 13, 2024

TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com

Dec 13, 2024

Nov 22, 2024

Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology

Nov 22, 2024

Nov 15, 2024

Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy

Nov 15, 2024

Nov 14, 2024

Ziopharm: Q3 Earnings Snapshot - The Washington Post

Nov 14, 2024

Nov 08, 2024

TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria

Nov 08, 2024

Oct 28, 2024

TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com

Oct 28, 2024

Oct 11, 2024

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance

Oct 11, 2024

Oct 10, 2024

Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com

Oct 10, 2024

Oct 10, 2024

Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch

Oct 10, 2024

Oct 01, 2024

Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena

Oct 01, 2024

Aug 23, 2024

VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology

Aug 23, 2024

Aug 14, 2024

Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology

Aug 14, 2024

Jul 16, 2024

Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com

Jul 16, 2024

Mar 27, 2024

Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology

Mar 27, 2024

Mar 25, 2024

Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology

Mar 25, 2024

Jan 30, 2024

Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks

Jan 30, 2024

Jan 25, 2024

Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology

Jan 25, 2024

Jan 24, 2024

NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena

Jan 24, 2024

Jan 23, 2024

Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology

Jan 23, 2024

Jan 04, 2024

BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology

Jan 04, 2024

Jan 03, 2024

Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology

Jan 03, 2024

Dec 18, 2023

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN

Dec 18, 2023

Nov 23, 2023

Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology

Nov 23, 2023

Nov 14, 2023

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance

Nov 14, 2023

Nov 09, 2023

Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology

Nov 09, 2023

Nov 01, 2023

AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology

Nov 01, 2023

Oct 26, 2023

How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology

Oct 26, 2023

Aug 17, 2023

StockWatch: Illumina Results Leave Investors, Analysts Anxious - Genetic Engineering and Biotechnology News

Aug 17, 2023

Aug 16, 2023

Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq

Aug 16, 2023

Aug 15, 2023

Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech

Aug 15, 2023

Jun 27, 2023

Houston BioTech Donation Enriches UH Program - University of Houston

Jun 27, 2023

Jun 21, 2023

15 Biotech Stocks Wall Street Analysts Say Are Too Cheap - Barron's

Jun 21, 2023

Jun 08, 2023

Hopewell Therapeutics raises funds for genomic medicines development - Pharmaceutical Technology

Jun 08, 2023

May 25, 2023

Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting - StockTitan

May 25, 2023

May 15, 2023

Alaunos Therapeutics upgraded to buy at Wainwright on multiple catalysts - Seeking Alpha

May 15, 2023

Apr 25, 2023

The past five years for Alaunos Therapeutics (NASDAQ:TCRT) investors has not been profitable - Yahoo Finance

Apr 25, 2023

Apr 04, 2023

Precigen Regains Exclusive Rights To Proven CAR-T Targets, CD19/BCMA - Contract Pharma

Apr 04, 2023

Apr 03, 2023

Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® - PR Newswire

Apr 03, 2023

Mar 30, 2023

Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors - citybiz

Mar 30, 2023